Neurology · 2022 · 112 citations · 31 references
Life SciencesNeurologyPharmacotherapyAutoimmunityClinical ImmunologyImmunotherapyDemyelinating DiseasesDemyelinating DisordersImmunosuppressionAntibody-mediated Neurologic DiseaseAquaporin-4 Antibody DiseaseLong-term EffectivenessLong-term Neurologic OutcomesMog Antibody DiseaseMog Antibody-associated DiseaseMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseRituximab-based Therapy
<h3>Background and Objectives</h3> Rituximab is used widely for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG–associated disease (MOGAD); however, data regarding the effectiveness and safety of long-term rituximab use in these conditions are limited. In this study, we sought to evaluate long-term clinical outcomes in patients with aquaporin-4 IgG–seropositive (AQP4-IgG+) NMOSD and MOGAD treated with rituximab. <h3>Methods</h3> We performed a retrospective chart review of patients with AQP4-IgG+ NMOSD or MOGAD followed at the Johns Hopkins Neuromyelitis Optica Clinic and included patients who had received at least 1 dose of rituximab. <h3>Results</h3> We identified 111 patients with NMOSD and 23 patients with MOGAD who fulfilled the inclusion criteria. The median duration of rituximab treatment for the patients with NMOSD was 3.7 years (range: 0.5–13.2 years) and for the patients with MOGAD was 2.1 years (range: 0.5–7.0 years). The annualized relapse rate (ARR) decreased after rituximab initiation in both NMOSD (median ARR: pretreatment 1.1, posttreatment 0; <i>p</i> < 0.001) and MOGAD (median ARR: pretreatment 1.9, posttreatment 0.3; <i>p</i> = 0.002). Relapses on rituximab occurred in 31 patients with NMOSD (28%) and 14 patients with MOGAD (61%). The majority of NMOSD treatment failures (37/48 relapses; 77%) occurred either within the initial 6 months after starting rituximab (n = 13 relapses) or in the setting of delayed/missed rituximab doses and/or peripheral B-cell reconstitution (n = 24 relapses), whereas in MOGAD, these circumstances were present in a smaller proportion of treatment failures (19/35 relapses; 54%). The risk of relapse on rituximab was greater for patients with MOGAD compared with patients with NMOSD (hazard ratio: 2.8, 95% CI: 1.5–5.2, <i>p</i> = 0.001). Infections requiring hospitalization occurred in 13% and immunoglobulin G (IgG) hypogammaglobulinemia in 17% of patients. The median rituximab treatment duration before IgG hypogammaglobulinemia onset was 5.4 years (interquartile range: 3.8–7.7 years). <h3>Discussion</h3> Rituximab treatment is associated with the reduced annualized relapse rate in AQP4-IgG–seropositive NMOSD, especially in the absence of gaps in treatment and/or B-cell reconstitution. In MOGAD, although a reduction in relapses was observed after initiation of rituximab, this association appeared to be less robust than in AQP4-IgG–seropositive NMOSD. Severe infections and hypogammaglobulinemia occurred in a significant proportion of patients, highlighting the need for close monitoring of infectious complications. <h3>Classification of Evidence</h3> This study provides Class IV evidence that rituximab decreases the annualized relapse rate in AQP4-IgG–seropositive NMOSD and MOGAD.
31
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology · 2015 · 4.5K citations · Full text
Medicine, Neurology, Neuroscience +15
Annabel M. Ruiter, Rosemarijn R. J. Somanje-Bolweg, Erik van Gorsel et al. · PubMed · 2017 · 1.8K citations · Full text
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 642 citations · Full text